Translational Development Acquisition Corp.

Translational Development Acquisition Corp., trading under the warrant ticker TDACW, is a blank-check company targeting the healthcare and life sciences sector, with its name reflecting a focus on bridging early-stage biomedical research and clinical application. The company filed an 8-K with the SEC on May 27, 2026, under accession number 0001104659-26-066599, representing a recent corporate disclosure. Sponsor details and IPO year have not been confirmed in available public records at this time. For complete filing history, sponsor identification, deal status, and real-time updates on TDACW, sign up for full access on SpacDesk.